REFERENCES
- Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, Jr., C. B., Gong, J., … Reeves, K. R. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax, 63(8), 717–724. doi: 10.1136 /thx.2007.090647
- Baran, X. Y., & Docherty, J. P. (2010). Rapid and sustained response to a single dose of sertraline in a patient with newly emergent depression during varenicline-assisted smoking cessation. CNS Spectrum, 15(3), 148–151.
- Campbell, A. R., & Anderson, K. D. (2010). Mental health stability in veterans with posttraumatic stress disorder receiving varenicline. American Journal of Health-System Pharmacy, 67(21), 1832–1837. doi: 10.2146/ajhp100196
- Coe, J. W., Brooks, P. R., Vetelino, M. G., Wirtz, M. C., Arnold, A. P., Huang, J., … O'Neil, B. T. (2005). Varenicline: An alpha4beta2 nicotinic receptor partial agonist for smoking cessation. Journal of Medicinal Chemistry, 48(10), 3474–3477. doi: 10.1021/jm050069n
- DiPaula, B. A., & Thomas, M. D. (2010). Worsening psychosis induced by varenicline in a hospitalized psychiatric patient. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 29(7), 852–857. doi: 10.1592/phco.29.7.852
- Freedman R. (2007). Exacerbation of schizophrenia by varenicline. American Journal of Psychiatry, 164(8), 1269. doi: 10.1176/appi.ajp.2007.07020326
- Jorenby, D. E., Hays, J. T., Rigotti, N. A., Azoulay, S., Watsky, E. J., Williams, K. E., … Reeves, K. R. (2006). Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296(1), 56–63. doi: 10.1001 / jama.296.1.56
- Moore, T. J., Furberg, C. D., Glenmullen, J., Maltsberger, J. T., & Singh, S. (2011). Suicidal behavior and depression in smoking cessation treatments. PloS ONE, 6(11), e27016. doi: 10.1371 /journal.pone.0027016
- Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., … Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical Pharmacology and Therapeutics, 30, 239–245. doi: 10.1038/clpt.1981.154
- Nides, M., Glover, E. D., Reus, V. I., Christen, A. G., Make, B. J., Billing, C. B., & Williams, K. E. (2008). Varenicline versus bupropion SR or placebo for smoking cessation: A pooled analysis. American Journal of Health Behavior, 32(6), 664–675. doi: http://dx.doi.org/10.5993/AJHB.32.6.10
- Nides, M., Oncken, C., Gonzales, D., Rennard, S., Watsky, E. J., Anziano, R., & Reeves, K. R. (2006). Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: Results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Archives of Internal Medicine, 166(15), 1561–1568.
- Slater, Y. E., Houlihan, L. M., Maskell, P. D., Exley R., Bermudez, I., Lukas, R. J., … Casells, B. K. (2003). Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes. Neuropharmacology, 44(4), 503–515.
- Tonstad, S., Tonneson, P., Hajek, P., Williams, K. E., Billing, C. B., & Reeves, K. R. (2006). Effect of maintenance therapy with varenicline on smoking cessation. Journal of the American Medical Association, 296(1), 64–71. doi: 10.1001/jama.296.1.64